Connective Tissue Diseases (Connective Tissue Disease)

Subscribe to Selected New Research on Connective Tissue Diseases

1692 relevant articles (46 outcomes, 159 trials/studies) found for this Disease

Description: A heterogeneous group of disorders, some hereditary, others acquired, characterized by abnormal structure or function of one or more of the elements of connective tissue, i.e., collagen, elastin, or the mucopolysaccharides.

Also Known As:

Connective Tissue Disease; Disease, Connective Tissue; Diseases, Connective Tissue

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Syndrome
2.	Hypertension (High Blood Pressure)
3.	Systemic Scleroderma (Systemic Sclerosis)
4.	Heart Diseases (Heart Disease)
5.	Osteoporosis

Experts

1.	Doria, A: 4 articles (12/2003 - 05/2000)
2.	Hirakata, Michito: 3 articles (01/2008 - 06/2003)
3.	Suwa, Akira: 3 articles (01/2008 - 06/2003)
4.	Lipworth, Loren: 3 articles (12/2007 - 06/2004)
5.	McLaughlin, Joseph K: 3 articles (12/2007 - 06/2004)
6.	Barst, Robyn J: 3 articles (12/2007 - 08/2004)
7.	Piette, Jean-Charles: 3 articles (11/2007 - 11/2003)
8.	Costedoat-Chalumeau, Nathalie: 3 articles (11/2007 - 11/2003)
9.	Amoura, Zahir: 3 articles (11/2007 - 11/2003)
10.	Takasaki, Yoshinari: 3 articles (07/2007 - 02/2004)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Connective Tissue Diseases:

1.	bosentan (Tracleer)FDA Link 02/01/2007 - "An improvement in AQOL measures at 3 months was also noted for patients with baseline WHO Functional Class III. CONCLUSIONS: Bosentan significantly improves quality of life in patients with idiopathic PAH or PAH associated with connective tissue diseases." 09/01/2006 - "CONCLUSION: Long-term treatment with bosentan was effective in improving exercise capacity and pulmonary haemodynamics in patients with PAH related to connective tissue diseases." 01/01/2007 - "This review critically appraises the evidence for the efficacy of bosentan in idiopathic and familial PAH, in PAH associated with connective tissue disease and in PAH which may develop in association with other conditions. " 02/01/2007 - "The VITAL study assessed the effect of bosentan on quality of life in patients with WHO Functional Class III or IV PAH (idiopathic or associated with connective tissue diseases). " 09/01/2008 - "METHODS: A total of 53 patients with PAH related to connective tissue diseases (PAH-CTD) in World Health Organization (WHO) functional class III received bosentan 62.5 mg twice a day for 4 weeks and then 125 mg twice a day for 44 weeks in this open non-comparative study. " Order ALL the reference details at left...
2.	AntibodiesIBA 01/01/2006 - "However, our knowledge on the pathogenesis of connective tissue diseases and the mechanisms of action of various antibodies is increasing, enabling improved disease control and reduction of adverse pregnancy outcomes. " 09/01/1997 - "ACA were present in 5% and anti-Scl-70 antibodies were present in 2% of patients with other connective tissue diseases, but fewer than 1% of disease free controls had either antibody present. " 03/01/2007 - "Data from recent experimental studies promote the hypothesis that U1-RNP antibodies participate in both innate and adaptive immune responses, implicating them in the pathogenesis of connective tissue disease." 06/01/2005 - "These results show that the PIP defect cannot be explained by low levels of C4A alone and suggest that measurements of anti-C1q antibodies may be useful in future studies on the molecular cause of the PIP defect in autoimmune connective tissue disease." 01/01/2000 - "OBJECTIVE: To study the frequency and disease specificity of antinucleosome antibody reactivity in diverse connective tissue diseases (CTD), and to determine factors, such as antibody subclass, that may influence the pathogenicity of these antibodies in relation to disease activity. " Order ALL the reference details at left...
3.	Antinuclear AntibodiesIBA 04/01/1996 - "Both the antinuclear antibody and extractable nuclear antibody tests are helpful in diagnosing connective tissue diseases. " 08/01/2009 - "The purpose of this study was to characterize the clinical and serological features of a large cohort of patients with antinuclear antibody (ANA) positive undifferentiated connective tissue disease (UCTD). " 11/01/2008 - "To ascertain the development of disease in a cohort of connective tissue disease (CTD)-negative patients 10 years after testing positive for antinuclear antibody (ANA) in high titer, a telephone survey and serological tests were conducted on a group of CTD-negative patients with high ANA titer identified in a previous study. " 01/01/1989 - "By indirect immunofluorescence studies of antinuclear antibodies on hamster liver imprints as a substrate performed to determine the nuclear staining pattern of sera from patients with connective tissue diseases 10 sera showed a distinct homogeneous nucleolar staining pattern associated with weaker speckled or homogeneous nucleoplasmic fluorescence. " 06/01/1987 - "A study of antinuclear antibodies (ANA) among Thai patients with various connective tissue diseases revealed that the prevalence of ANA was similar to that in other countries, but that the ANA patterns showed interesting contrasts in most diseases. " Order ALL the reference details at left...
4.	sildenafil (Viagra)FDA Link 01/01/2008 - "Oral sildenafil 20 mg three times daily added to conventional background therapy was significantly more effective than placebo at increasing exercise capacity in patients with idiopathic PAH or PAH associated with connective tissue diseases or repaired congenital systemic-to-pulmonary shunts. " 11/01/2007 - "BACKGROUND: Sildenafil is a selective inhibitor of phosphodiesterase type 5 (PDE5), and has been shown to improve 6-minute walk distance (SMWD) and World Health Organization (WHO) functional class in patients with idiopathic pulmonary arterial hypertension (iPAH) and PAH associated with connective tissue disease or with repaired congenital systemic-to-pulmonary shunts. " 01/01/2007 - "Analysis of results of randomized controlled studies assessing efficacy and safety of sildenafil in patients with primary (idiopathic) PAH and PAH associated with connective tissue diseases and congenital heart diseases with systemic-to-pulmonary shunts is presented." 11/17/2005 - "METHODS: In this double-blind, placebo-controlled study, we randomly assigned 278 patients with symptomatic pulmonary arterial hypertension (either idiopathic or associated with connective-tissue disease or with repaired congenital systemic-to-pulmonary shunts) to placebo or sildenafil (20, 40, or 80 mg) orally three times daily for 12 weeks. " 01/01/2009 - "Many health care practitioners may be unaware that sildenafil is also marketed under the brand name Revatio for treatment of primary pulmonary hypertension or pulmonary hypertension secondary to connective tissue disease. " Order ALL the reference details at left...
5.	Etidronic Acid (HEDP)FDA LinkGeneric 12/01/2003 - "CONCLUSION: These results indicate that intermittent cyclical etidronate therapy is effective for the prevention and treatment of corticosteroid induced osteoporosis in patients with connective tissue diseases." 01/01/2008 - "CONCLUSION: Our results indicate that longterm (up to 7 years) intermittent cyclical etidronate therapy is safe and effective for prevention and treatment of corticosteroid-induced osteoporosis in patients with connective tissue diseases." 01/01/2000 - "Efficacy of intermittent etidronate therapy for corticosteroid-induced osteoporosis in patients with diffuse connective tissue disease." 01/01/2008 - "Longterm effect of intermittent cyclical etidronate therapy on corticosteroid-induced osteoporosis in Japanese patients with connective tissue disease: 7-year followup." 12/01/2003 - "Effect of intermittent cyclical etidronate therapy on corticosteroid induced osteoporosis in Japanese patients with connective tissue disease: 3 year followup." Order ALL the reference details at left...
6.	sitaxsentanIBA 11/01/2004 - "In its first randomised, placebo-controlled study, Sitaxsentan to Relieve Impaired Exercise-1 (STRIDE-1), sitaxsentan improved exercise capacity assessed by 6 min walk, New York Heart Association functional class, cardiac index and pulmonary vascular resistance in New York Heart Association class II, III and IV patients with idiopathic PAH, PAH related to connective tissue disease or PAH related to congenital heart disease. " 03/01/2009 - "Further evaluation of sitaxsentan in patients with connective tissue diseases suffering from ischemic skin ulcers is required." 05/01/2008 - "Is sitaxsentan a good therapeutic option for pulmonary arterial hypertension associated with connective tissue disease?" 01/01/2007 - "METHODS: Forty-eight patients with idiopathic PAH or PAH associated with connective-tissue disease or congenital heart disease were randomized (double-blind) to a single daily dose of either 50 mg or 100 mg sitaxsentan. " 11/01/2005 - "In its first randomized, placebo-controlled study, sitaxsentan improved exercise capacity assessed by the 6-min walk test, New York Heart Association functional class, cardiac index and pulmonary vascular resistance in New York Heart Association Class II, III and IV patients with idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension related to connective tissue disease or congenital heart disease. " Order ALL the reference details at left...
7.	Intravenous Immunoglobulins (IVIG)FDA Link 11/01/1991 - "Further investigation in the treatment of connective tissue diseases with intravenous immunoglobulins is suggested. " 11/01/2007 - "We aimed to investigate the frequency and profile of adverse events in a group of patients with diffuse connective tissue diseases and Wegener's granulomatosis (WG) who were administrated HD-IVIG for different indications. " 04/01/2005 - "High-dose IVIG may be used as an adjunctive treatment in connective tissue diseases that do not respond to standard therapies or as alternative treatment for patients with concurrent severe infections or for whom immunosuppressives are contraindicated." 05/01/1994 - "Although clearly demonstrated in idiopathic thrombocytopenic purpura and Kawasaki disease, the efficacy of intravenous immunoglobulins in the treatment of rheumatic and connective tissue diseases remains to be confirmed in double-blind placebo-controlled studies. " 01/01/2008 - "The case reports (one patient with lupus erythematosus chorea, two patients with dermatomyositis and one with the Wegener's granulomatosis) present a treatment of systemic connective tissue diseases with IVIg following the failure of standard therapeutic regimens. " Order ALL the reference details at left...
8.	Cyclophosphamide (Cytoxan)FDA LinkGeneric 08/01/1997 - "CONCLUSION: Treatment of severe connective tissue diseases with 'low dose' intravenous cyclophosphamide pulses compares in efficacy with the higher monthly doses previously advocated. " 07/01/1992 - "It is concluded that low dose pulses of intravenous cyclophosphamide are well tolerated and are an effective treatment for patients with aggressive connective tissue diseases." 08/01/1997 - "PATIENTS: Ninety patients (68F:22M) with severe connective tissue diseases received a total of 883 cyclophosphamide pulses with 78 of 90 patients initially having weekly 500 mg pulses for a median of three (2-10) weeks. " 08/01/1997 - "OBJECTIVE: To review our experience with low dose intravenous pulse cyclophosphamide in the treatment of patients with severe connective tissue diseases. " 08/01/1997 - "Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide." Order ALL the reference details at left...
9.	Trimethoprim-Sulfamethoxazole Combination (Co-Trimoxazole)FDA LinkGeneric 01/01/2005 - "We performed a retrospective analysis to establish a statistical model for the prediction of Pneumocystis pneumonia (PCP) in patients with connective tissue diseases (CTD) undergoing medium- or high-dose corticosteroid therapy, to identify independent risk factors for PCP and to evaluate the efficacy of the prophylactic use of trimethoprim-sulfamethoxazole (TMP/SMX) against PCP. " 05/01/2008 - "Comparison of trimethoprim-sulfamethoxazole and aerosolized pentamidine for primary prophylaxis of Pneumocystis jiroveci pneumonia in immunocompromised patients with connective tissue disease." 05/01/2008 - "To evaluate the efficacy of primary prophylaxis for Pneumocystis jiroveci pneumonia (PCP) in patients with connective tissue disease (CTD) and immunosuppression, we compared trimethoprim-sulfamethoxazole (TMP-SMZ) with aerosolized pentamidine. " Order ALL the reference details at left...
10.	SiliconesIBA 01/01/1998 - "Recent studies have shown no correlation between silicone implants and connective tissue disease." 04/01/1994 - "However the cause-effect relationship between silicone and scleroderma/other connective tissue disease requires, not just anecdotal reports, but a rigorously designed study." 01/01/1994 - "These studies strengthen the concept that there is no conclusive evidence that silicone-gel implants are related to the development of connective tissue disease." 07/01/1993 - "Further studies are necessary to elucidate the role of silicone, if any, in the pathogenesis of autoimmune connective tissue disease. " 01/01/2007 - "Silicone implants and connective tissue disease: 5 cases." Order ALL the reference details at left...

Therapies and Procedures

1.	Transplants (Transplant) 03/01/2002 - "Eight out of the 11 acute patients had chronic hemolytic disorder as the underlying disease while, the 3 other patients were organ transplant and connective tissue disease patients. " 07/01/1965 - "CONNECTIVE-TISSUE DISEASE AND RHEUMATOID FACTORS IN PATIENTS WITH RENAL TRANSPLANTS." 12/01/2006 - "CONCLUSION: This case highlights the pitfalls of stent-graft repair in a patient with presumed connective tissue disease." 09/01/1986 - "This article examines contraception in adolescents with hematologic, oncologic, dermatologic, and psychiatric disorders, connective tissue diseases, and renal disease and transplants. " 05/01/2003 - "Corticotherapy is provided in many disorders such as autoimmune connective tissue diseases, different types of cancer, blood dyscrasias and transplant patients, among others. " Order ALL the reference details at left...
2.	Prostheses and Implants (Prosthesis) 03/01/2002 - "CONCLUSION: Our findings suggest that the risk of connective-tissue diseases is not higher in patients wearing prostheses as the ANA is negative and there is no apparent manifestation suggestive of connective-tissue diseases." 03/01/2002 - "AIM: To help clarifying the possibility of connective-tissue diseases in men with penile or testicular prostheses. " 06/01/2000 - "Connective tissue disease and other related rheumatic conditions among patients with finger and hand and temporomandibular joint prostheses in Denmark." 01/11/1993 - "Implantation of prostheses filled with saline are recommended for patients with connective tissue disease." 02/28/1992 - "Although evidence of a causal relationship between the implantation and the development of connective tissue disease is circumstantial, removal of the silicone prosthesis has been reported to result in subsequent remission." Order ALL the reference details at left...
3.	Aftercare (After-Treatment) 12/01/1991 - "Recovery of renal function in undifferentiated connective tissue disease after treatment with angiotensin-converting enzyme inhibitors." 04/01/1999 - "This report concerns two Filipino women, one with dermatomyositis, the other with undifferentiated connective tissue disease, who showed significant reduction of widespread calcinosis after treatment with diltiazem. " 05/01/2006 - "We report the case of female patient with systemic lupus erythematosus who, after treatment with terbinafine, presented a Stevens Johnson syndrome eruption, together with renal exacerbation of her connective tissue disease. " 04/01/2001 - "We evaluated the plasma concentrations of soluble adhesion molecules, platelet activation markers, and platelet-derived microparticles (PMPs) in patients with connective tissue diseases who had secondary hyperlipidemia caused by long-term steroid administration (n = 22) before and after treatment with bezafibrate. " 05/01/1979 - "Urinary neutral oligosaccharides of various connective tissue diseases were studied by gel-filtration through Sephadex G--10 after treatments with cetylpyridinium chloride (CPC), Dowex 50 (H+ form) and Dowex 1 (Cl- form), in succession. " Order ALL the reference details at left...
4.	Phototherapy (Light Therapy) 09/20/2004 - "UVA/UVA1 phototherapy and PUVA photochemotherapy in connective tissue diseases and related disorders: a research based review." 09/01/1999 - "The constantly increasing use of UVA-1 phototherapy has not only improved UVA phototherapy for established indications such as atopic dermatitis (Krutmann et al, 1992a, 1998; Krutmann, 1996), but has also provided dermatologists with the opportunity to successfully treat previously untractable skin diseases, e.g., connective tissue diseases (Stege et al, 1997; Krutmann, 1997). " Order ALL the reference details at left...
5.	Combination Drug Therapy (Combination Chemotherapy) 07/01/1988 - "When Hodgkin's disease later developed the patient received combination chemotherapy, which induced remission of both neoplastic and connective tissue diseases. " Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Connective Tissue Diseases

*WARNING* This specific disease subtype has a relatively small number of significant evidence outcomes. You may proceed to order anyway, or go back to the search field and enter a more general type of the target illness. Once your report has been ordered, however, we can't refund the purchase.

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 46 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>